CinCor Pharma, Inc.
CinCor Pharma, Inc.
Share · US17240Y1091 · CINC (XNAS)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,00 % 81,62 %

Company Profile for CinCor Pharma, Inc. Share

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Company Data

Name CinCor Pharma, Inc.
Company CinCor Pharma, Inc.
Symbol CINC
Website https://www.cincor.com
Primary Exchange XNAS NASDAQ
ISIN US17240Y1091
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Marc M. P. de Garidel
Market Capitalization 1 Mrd.
Country United States of America
Currency USD
Employees 0,0 T
Address 200 Clarendon Street, 02116 Boston
IPO Date 2022-01-07

Ticker Symbols

Name Symbol
NASDAQ CINC

More Shares

Investors who CinCor Pharma, Inc. hold also have the following shares in their portfolio:
GORES HOLDINGS V INC- UNIT
GORES HOLDINGS V INC- UNIT Share
REALNETWORKS INC
REALNETWORKS INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025